AMGEN INC (AMGN)

As of 14 August 2026, short interest in AMGN is 12,039,849 shares, down 805,159 shares over the last month. Over the last 48 readings it ranged from 8,477,354 shares (30 August 2024) to 16,158,990 shares (28 February 2025). At the reported average volume of 2.8M shares a day that is 4.3 days to cover.

<iframe src="https://xoomar.com/embed/stocks/amgn" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 11 September 2026, the short share of AMGN volume is 41.0%, down 16.3 points over the last five sessions. Over the last 52 readings it ranged from 34.8% (18 August 2026) to 78.0% (30 July 2026). The latest reading is 11.7 points below the 30-session average of 52.7%, on 855K shares reported.

As of 14 August 2026, the fails-to-deliver balance in AMGN is 144 shares, down 7,611 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (17 April 2026) to 208,764 shares (23 March 2026). The latest reading sits at the bottom of that range.

Insiders at AMGN reported 6 open-market sells worth $4.1M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Khosla Rachna (SVP, Business Development) on 2026-08-13.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

4 Form 144 notices on file for AMGN worth $3.7M at the prices reported; 4 in the last 90 days worth $3.7M. Latest: Khosla Rachna filed on 2026-08-13 to sell 1,252 shares ($517K) from 2026-08-13.

8 of the 30 tracked managers held AMGN at their latest 13F, $2.68B in total at quarter-end prices. Citadel Advisors is the largest at $894.2M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 2 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 2026 (quarter ended 2026-06-30) AMGEN INC reported revenue of $10.05B, up 9.5% from the same quarter a year earlier, and net income of $2.38B (4.37 diluted EPS). In FY 2025 it generated $9.96B of operating cash flow and spent $5.12B on dividends. As of 2026-06-30, cash was $13.99B against $57.30B of debt.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-30 from the cover page.

1 contract action on file for AMGN: $66.0M obligated in the last 90 days and $66.0M in the last 12 months across 1 awarding agency. The largest was $66.0M from the Department of Health and Human Services on 2026-08-04 (eo14398 for far 52.222-90, updated hhsar and exercise option period 4a for $65,698,998.00). Only actions large enough to reach the daily top list are counted, and agencies report with a lag.